Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 4Endocrine 2Thoracic 1NET 1Lymphoid 1Head & Neck 1Gastrointestinal 1

Conditions

Neuroendocrine Tumors 10Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Pulmonary Neuroendocrine Tumor 1Neuroendocrine Tumor Grade 3 1Neoplasm Metastasis 1Colorectal Neoplasms 1

Interventions

Fluorodeoxyglucose F18 2tivozanib 1tislelizumab 1surufatinib 1romidepsin 1repotrectinib 1regorafenib 1fludarabine phosphate 1fludarabine 1entrectinib 1atezolizumab 1alectinib 1Quality of Life 1Patient Reported Outcome Measures 1PM 01183 1Nivolumab 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Lactones 1Irinotecan 1Interleukin-2 1Immunotherapy 1FAPI-46 1Drug Therapy 1Depsipeptides 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × surufatinib × NET × Clear all
NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
87 enrolled 29 charts
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡